Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-04
2011-01-04
Duffy, Patrica A (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S340000
Reexamination Certificate
active
07863425
ABSTRACT:
The invention provides a gene transfer vector for inducing an immune response againstYersinia pestisin a mammal. The gene transfer vector comprises a nucleic acid sequence encoding an immunogenic portion of one or more proteins ofYersinia pestisand/or a nucleic acid sequence encoding a monoclonal antibody directed againstYersinia pestis. The invention further provides a method of producing an immune response againstYersinia pestisin a mammal comprising administration of the gene transfer vector to the mammal. The invention also provides a monoclonal antibody directed against the Virulence (V) antigen ofY. pestis, as well as a hybridoma cell line producing same and a nucleic acid sequence encoding same.
REFERENCES:
Anderson et al., “Recombinant V Antigen Protects Mice against Pneumonic and Bubonic Plague Caused by F1-Capsule-Positive and -Negative Strains ofYersinia pestis,” Infec. Immun., 64: 4580-4585 (1996).
Bennett et al., “Gene gun mediated vaccination is superior to manual delivery for immunization with DNA vaccines expressing protective antigens fromYersinia pestisor Venezuelan Equine Encephalitis virus,” Vaccine, 18: 588-596 (1999).
Green et al., “The SCID/Beige mouse as a model to investigate protection againstYersinia pestis,” FEMS Immunol. Med. Microbiol., 23: 107-113 (1999).
Hersh et al., “Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector,” Gene Ther., 2: 124-131 (1995).
Hill et al., “Regions ofYersinia pestisV Antigen That Contribute to Protection against Plague Identified by Passive and Active Immunization,” Infect. Immun., 65(11): 4476-4482 (1997).
Ingelsby et al., “Plague as a Biological Weapon,” JAMA, 283: 2281-2290 (2000).
Kilonzo et al., “A decade of plague epidemiology and control in the Western Usambara mountains, north-east Tanzania,” Acta Tropica, 50: 323-329 (1992).
Leary et al., “Active Immunization with Recombinant V Antigen fromYersinia pestisProtects Mice against Plague,” Infect. Immun., 63: 2854-2858 (1995).
Meyer, “Therapy of Plague,” JAMA, 144: 982-985 (1950).
Motin et al., “Passive Immunity toYersiniaeMediated by Anti-Recombinant V Antigen and Protein A-V Antigen Fusion Peptide,” Infect. Immun., 62: 192-201 (1994).
Mwengee et al., “Treatment of Plague with Gentamicin or Doxycycline in a Randomized Clinical Trial in Tanzania,” Clin. Infect. Dis., 42: 614-621 (2006).
Parkhill et al., “Genome sequence ofYersinia pestis, the causative agent of plague,” Nature, 413 (6855): 523-527 (2001).
Perry et al., “Yersinia pestis—Etiologic Agent of Plague,” Clin. Microbiol. Rev., 10: 35-66 (1997).
Pettersson et al., “The V-antigen ofYersiniais surface exposed before target cell contact and involved in virulence protein translocation,” Mol. Microbiol., 32: 961-976 (1999).
Russell et al., “A comparison of Plague vaccine, USP and EV76 vaccine induced protection againstYersinia pestisin a murine model,” Vaccine, 13: 1551-1556 (1995).
Sarker et al., “TheYersiniaYop Virulon: LcrV Is Required for Extrusion of the Translocators YopB and YopD,” J. Bacteriol., 180: 1207-1214 (1998).
Smego et al., “YersiniosisI: Microbiological and Clinicoepidemiological Aspects of Plague and Non-PlagueYersiniaInfections,” Eur. J. Clin. Microbial. Infect. Dis., 18: 1-15 (1999).
Sofer-Podesta et al., “Protection Against a LethalYersinia pestisChallenge by an Anti-V Antigen Monoclonal Antibody Delivered with an Adenovirus Gene Transfer Vector,” Molecular Therapy, 16 (Suppl. 1): S268 (2008).
Titball et al., “Yersinia pestis(plague) vaccines,” Expert Opin. Biol Ther., 4: 965-973 (2004).
Titball et al, “Vaccination against bubonic and pneumonic plague,” Vaccine, 19: 4175-4184 (2001).
Titball et al, “Plague,” in Plotkin et al., eds., Vaccine, WB Saunders, Philadelphia, p. 999 (2004).
Wagle, “Recent Advances in the Treatment of Bubonic Plague,” Indian J. Med. Sci., 2: 489-494 (1948).
Wang et al., “A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague,” Vaccine, 22: 3348-3357 (2004).
Williamson et al, “Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague,” Vaccine, 20: 2933-2941 (2002).
Boyer et al.,Am. Soc. Gene Ther. 10thAnnual Meeting, Abstract # 450970 (2007).
Chiuchiolo et al.,Mol. Ther., 9, S215, Abstract # 570 (2004).
Chiuchiolo et al.,Mol. Ther., 11, S27, Abstract # 67 (2005).
Chiuchiolo et al.,Mol. Ther., 13, S423, Abstract # 605 (2006).
Sofer-Podesta et al.,Am. Soc. Gene Ther. 10thAnnual Meeting, Abstract # 450724 (2007).
Boyer Julie L
Crystal Ronald G
Cornell University
Duffy Patrica A
Leydig , Voit & Mayer, Ltd.
LandOfFree
Compositions and methods for inhibiting Yersinia pestis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting Yersinia pestis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting Yersinia pestis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620778